RB Capital Management LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 9.8% during the third quarter, HoldingsChannel reports. The institutional investor owned 7,194 shares of the company’s stock after acquiring an additional 641 shares during the period. RB Capital Management LLC’s holdings in Johnson & Johnson were worth $1,066,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently bought and sold shares of JNJ. Nordea Investment Management AB grew its position in shares of Johnson & Johnson by 88.0% in the 2nd quarter. Nordea Investment Management AB now owns 17,222,162 shares of the company’s stock valued at $2,382,514,000 after buying an additional 8,062,204 shares during the last quarter. BlackRock Inc. grew its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. BlackRock Inc. now owns 193,714,044 shares of the company’s stock valued at $27,242,005,000 after buying an additional 1,168,129 shares during the last quarter. California Public Employees Retirement System grew its position in shares of Johnson & Johnson by 8.9% in the 3rd quarter. California Public Employees Retirement System now owns 10,616,780 shares of the company’s stock valued at $1,580,626,000 after buying an additional 864,547 shares during the last quarter. MUFG Securities EMEA plc grew its position in shares of Johnson & Johnson by 124.7% in the 2nd quarter. MUFG Securities EMEA plc now owns 1,506,456 shares of the company’s stock valued at $211,853,000 after buying an additional 836,139 shares during the last quarter. Finally, Handelsbanken Fonder AB grew its position in Johnson & Johnson by 290.9% during the 2nd quarter. Handelsbanken Fonder AB now owns 1,114,004 shares of the company’s stock worth $156,662,000 after purchasing an additional 829,053 shares during the last quarter. 67.44% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE JNJ opened at $143.68 on Friday. The company has a quick ratio of 1.24, a current ratio of 1.48 and a debt-to-equity ratio of 0.51. Johnson & Johnson has a 52 week low of $109.16 and a 52 week high of $157.00. The firm has a 50-day moving average price of $145.31 and a 200 day moving average price of $146.47. The stock has a market capitalization of $378.24 billion, a price-to-earnings ratio of 22.59, a price-to-earnings-growth ratio of 3.04 and a beta of 0.69.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a net margin of 21.01% and a return on equity of 34.64%. The firm had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. During the same quarter last year, the business earned $2.12 earnings per share. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. Equities research analysts expect that Johnson & Johnson will post 7.99 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be paid a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.81%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio (DPR) is 46.54%.
Several research analysts have issued reports on the stock. Stifel Nicolaus downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. ValuEngine raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. Cantor Fitzgerald raised their price objective on shares of Johnson & Johnson from $168.00 to $180.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. Credit Suisse Group raised their target price on shares of Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Finally, Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday, November 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and ten have given a buy rating to the company’s stock. Johnson & Johnson presently has an average rating of “Buy” and a consensus target price of $164.93.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 16,115 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $153.52, for a total transaction of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by company insiders.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Read More: What is the Ex-Dividend Date in Investing?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.